Canonical CD47-SIRPα targeted therapeutics are antibodies, but small molecular inhibitors that target CD47-SIRPα binding and CD47 expression have emerged as better choices due to their preferable tumor accessibility [170,171] even though CD47 is also expressed on erythrocytes; thus systematic administration of CD47 inhibitor may cause anemia as a severe side effect [172]. Here, SIRPA is linked to neoplasm.